Evommune, Inc. (EVMN)

Evommune, Inc. (EVMN) is a Biotechnology company in the Healthcare sector listed on the NYSE.

As of Oct 23, 2026: market cap $188M; returns 1 day -2.1%, 1 week -1.4%.

Evommune Inc. (EVMN) is a clinical-stage biotechnology company focused on developing innovative therapies that target key drivers of chronic inflammatory diseases. The company's pipeline includes EVO756, an oral small molecule antagonist of MRGPRX2, and EVO301, a long-acting injectable designed to neutralize IL-18.

Groups EVMN belongs to

• Healthcare
• Biotechnology
• Clinical Stage Biotech
• Recent IPOs
• Chronic Inflammatory Diseases
• Autoimmune Diseases
• Dermatology
• Long-Acting Injectables
• Gastroenterology

EVMN financial model: income statement, cash flow and balance sheet